Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 11/20 | 0.47 |
| ▸ | TP53 | P04637 | 8/20 | 0.47 |
| ▸ | FDFT1 | P37268 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4466269 | 0.90 | MDM2 (0.45) | MDM2TP53FDFT1KDM4EHPGD | |
| SCHEMBL4468907 | 0.86 | NPC1 (0.38) | MDM2TP53KDM4EPOLBALOX15 | |
| SCHEMBL4473969 | 0.85 | EDNRB (0.38) | MDM2TP53KDM4EMCL1FFAR1 | |
| SCHEMBL27568972 | 0.85 | ALDH1A1 (0.43) | MDM2TP53KDM4EHPGD | |
| SCHEMBL4466885 | 0.85 | FFAR1 (0.38) | MDM2TP53FDFT1KDM4EHPGD | |
| SCHEMBL13708554 | 0.84 | MDM2 (0.37) | MDM2TP53KDM4EHPGDMCL1 | |
| SCHEMBL4474014 | 0.83 | FFAR4 (0.40) | MDM2TP53KDM4EPOLBALOX15 | |
| SCHEMBL4466929 | 0.83 | DNMT1 (0.38) | MDM2TP53KDM4EMCL1FFAR1 | |
| SCHEMBL4467132 | 0.82 | MDM2 (0.38) | MDM2TP53KDM4EHPGDMCL1 | |
| SCHEMBL4474552 | 0.82 | CTDSP1 (0.41) | MDM2TP53KDM4EPOLBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589117-B2 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-15 | — | — | US | disclosed |
| US-7078428-B2 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-18 | — | — | US | disclosed |
| US-20060148880-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
| EP-1528923-B1 | N-((3-OXO-2,3-DIHYDRO-1H-ISOINDOL-1-YL)ACETYL)GUANIDINE DERIVATIVES AS NHE1-INHIBITORS FOR THE TREATMENT OF INFARCTION AND ANGINA PECTORIS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-05-03 | — | — | EP | disclosed |
| EP-1528923-A1 | N-((3-OXO-2,3-DIHYDRO-1H-ISOINDOL-1-YL)ACETYL)GUANIDINE DERIVATIVES AS NHE1-INHIBITORS FOR THE TREATMENT OF INFARCTION AND ANGINA PECTORIS | Aventis Pharma Deutschland GmbH (DE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040048916-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUSCHLAND GMBH (DE) | 2004-03-11 | — | — | US | disclosed |
| WO-2003101450-A1 | N- ((3-OXO2, 3-DIHYDRO-1H-ISOINDOL-1-YL) ACETYL) GUANIDINE DERIVATIVES AS NHE-1 INHIBITORS FOR THE TREATMENT OF INFARCTION AND ANGINA PECTORIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148880-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | TNNI3, NDUFB3, NDUFB11 | MDM2 1402/4885TP53 2869/4885FDFT1 418/4885 |
| US-20040048916-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | TNNI3, NDUFB3, NDUFB11 | MDM2 1566/4885TP53 3009/4885FDFT1 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.